340B
Manufacturer updates
AbbVie
Effective January 1, 2025, Grantee covered entities that wish to facilitate bill to/ship to orders must register with 340B ESP and submit limited claims data on the 340B contract pharmacy utilization. There has also been a change to the Abbvie NDCS impacted by this policy. For more information, please visit https://340besp.com/
Effective August 28, 2024, AbbVie will exempt Missouri covered entities from its 340B contract pharmacy policy.
Contact:
support@340besp.com
Effective August 1, 2024, AbbVie will no longer extend 340B-like voluntary pricing on its orphan-designated drugs to covered entities subject to the orphan drug exclusion. This change will not impact separate agreements with impacted covered entities.
Contact:
support@340besp.com
Contact:
support@340besp.com
Contact:
support@340besp.com
Effective May 1, 2024, AbbVie will include Venclexta products in its 340B contract pharmacy policy. Federal Grantees are not subject to limitations.
Contact:
support@340besp.com
Contact:
support@340BESP.com
*Imbruvica effective April 1st, 2022
Contact:
support@340BESP.com
Alkermes
support@340besp.com
Contact:
support@340besp.com
Contact:
support@340besp.com
Amgen
Effective August 28, 2024, Amgen will exempt Missouri hospital covered entities from its 340B contract pharmacy policy
Contact:
support@340besp.com
Contact:
support@340besp.com
Contact:
support@340besp.com
Contact:
support@340besp.com
Contact:
support@340BESP.com
Contact:
support@340Besp.com
Contact:
340Brelations@amgen.com
Astellas
Federal Grantees and covered entities in the state of Alabama* and Louisiana* are not subject to limitations.
*For contract pharmacies within the respective states
Contact:
support@340besp.com
Contact:
support@340besp.com
Contact:
support@340BESP.com
AstraZeneca
Contact: support@340BESP.com
Contact: support@340BESP.com
*Calquence & Lynparza (October 1st, 2022) and Fasenra (January 1st, 2023) voluntary contracts restored.
Contact:
Contact:
Bausch Health
Contact:
support@340besp.com
Contact:
support@340BESP.com
Contact:
support@340Besp.com
Bausch & Lomb
Contact:
support@340Besp.com
Bayer
Effective October 1, 2024, Bayer will change to their 340B contract pharmacy policy to add federal grantees to their policy and require data submission within 45 days of date of dispense utilizing 340B ESP for all covered entities.
Contact:
support@340besp.com
Contact:
support@340besp.com
Contact:
support@340besp.com
*Updated policy now includes Adempas
Contact:
support@340BESP.com
Contact:
support@340Besp.com
Biogen
Effective January 20, 2025 Biogen has made changes to their 340B contract pharmacy policy regarding all 340B covered entities (including hospital covered entities, federal grantee covered entities, and all contract pharmacies including wholly owned pharmacies). Data submission is also required via 340B ESP. Arkansas, Louisiana, Kansas, Maryland, Minnesota, Missouri, Mississippi, and West Virigina are excluded from this policy.
Federal Grantees not subject to limitations.
Contact:
support@340besp.com
Contact:
support@340BESP.com
Boehringer Ingelheim
Contact:
support@340Besp.com
Contact:
support@340Besp.com
Contact:
support@340Besp.com
Any covered entity that does not have an in-house pharmacy capable of dispensing specialty products may designate 1 specialty pharmacy from within BI’s limited distribution network for the purpose of dispensing OFEV.
Contact:
support@340BESP.com
Contact:
support@340besp.com
Contact:
support@340Besp.com
Bristol Myers Squibb
October 22, 2024, Update: On October 22, 2024, BMS notified HRSA of BMS’ intention to implement a rebate model to carry out their 340B pricing obligations with an effective date of Spring 2025
November 26, 2024, Update: BMS sued HRSA over its purported rejection of BMS’ plan to change the way it offers reduced prices on its medicines in the 340B program.
Contact:
BMS340B@bms.com
As announced by the BMS third party solution, they have capabilities to accept serialization as of 9/3/2024. Per BMS, they are deferring the requirement for covered entities to submit the product serialization number to allow for additional time for DSCSA compliance stabilization. FDA exemption for serialization requirements for manufacturers through May 27th, 2025.
Contact:
BMS340B@bms.com
Effective October 1, 2024, BMS will allow for a fourth contract pharmacy for Krazati ®
Contact:
BMS340B@bms.com
Contact:
BMS340B@bms.com
Contact:
support@340besp.com
Contact:
BMS340B@bms.com
Contact:
BMS340B@bms.com
Contact:
BMS340B@bms.com
locations per 340B hospital that lacks an entity-owned pharmacy: one for IMiDs and a second for non-IMiDs. Federal Grantees not subject to limitations on non-IMiD products.
*Camzyos effective July 1st, 2022
Contact:
BMS340B@bms.com
Clovis
At this time, Clovis wonāt be implementing its partnership with Kalderos to effectuate 340B drug discounted prices for 340B Contract Pharmacies. Clovisā products remain available through all historically available channels.
Contact:
priceadmin@clovisoncology.com
Eisai
Federal Grantees not subject to limitations.
*Additional contract pharmacy options may be available to Arkansas and Louisiana hospital covered entities
Contact:
support@340besp.com
EMD Serono
Contact:
support@340BESP.com
Contact:
support@340BESP.com
*Serostim®: covered entities may designate one additional contract pharmacy location in EMDS’s secure distribution network (the “SND”) for the purpose of dispensing Serostim only.
Federal Grantees not subject to limitations.
Contact:
support@340besp.com
Contact:
support@340Besp.com
Eli Lilly
August 2024 Update: In August 2024, Lilly notified HRSA of Lilly’s intention to implement its obligation to offer the 340B ceiling price to covered entities through a rebate via a cash replenishment model, for an effective date of November 1, 2024.
November 15, 2024 Update: Lilly sued HRSA over its purported rejection of Lilly’s plan to change the way it offers reduced prices on its medicines in the 340B program, through its technology partner Kalderos.
Contact:
340B@lilly.com
Contact:
340B@lilly.com
Contact:
340B@lilly.com
Contact:
340B@lilly.com
Effective September 1st, 2020, Lilly restricted access for 340B priced product to Contract Pharmacies, except insulin.
Contact:
340B@lilly.com
Exelixis
Contact:
340B@exelixis.com
Contact:
340B@exelixis.com
Genentech
Federal Grantees are not subject to limitations.
Contact:
support@340besp.com
Gilead
Contact:
support@340besp.com
Contact:
support@340BESP.com
GlaxoSmithKline
Effective August 28, 2024, GSK will exempt Missouri hospital covered entities from its 340B contract pharmacy policy
Effective August 1, 2024, GSK will allow covered entities located in Minnesota to place “Bill to/Ship to” replenishment orders to their HRSA designated contract pharmacies located within the state. For specialty/oncology products part of the limited pharmacy network, the contract pharmacies must be a part of GSK’s limited pharmacy network.
Contact:
support@340besp.com
Effective August 1, 2024, GSK will allow covered entities located in Minnesota to place “Bill to/Ship to” replenishment orders to their HRSA designated contract pharmacies located within the state. For specialty/oncology products part of the limited pharmacy network, the contract pharmacies must be a part of GSK’s limited pharmacy network.
Contact:
support@340besp.com
Contact:
support@340besp.com
Contact:
support@340besp.com
GSK will honor Arkansas- and Louisiana-based covered entities’ replenishment orders associated with a covered product dispensed within the respective states on or after August 1st, 2023.
Contact:
support@340besp.com
Contact:
support@340besp.com
*Updated policy now includes all GSK drugs
Contact:
support@340BESP.com
Contact:
US.340B@gsk.com
Contact
support@340Besp.com
Incyte
Federal Grantees are not subject to limitations.
Contact:
support@340BESP.com
Jazz
Federal Grantees not subject to limitations.
Contact:
support@340besp.com
Janssen
Effective July 1, 2024, Johnson & Johnson will allow non-grantee entities located in Maryland and Mississippi to place “Bill to/Ship to” replenishment orders to their HRSA designated contract pharmacies located within the respective states through the provision of claims data.
Contact:
340B_JJHCS@its.jnj.com
Contact:
340B_JJHCS@its.jnj.com
Effective January 1st, 2022, Janssen will no longer offer voluntary 340B pricing on orphan drugs to Covered Entities subject to the 340B orphan drug exclusion. This change will not impact separate agreements with impacted Covered Entities.
Contact:
340B_JJHCS@its.jnj.com
Johnson & Johnson
Effective 9/30/2024, Johnson and Johnson will postpone their 340B Rebate Program announced on 8/23/2024. Additionally, effective 8/20/2024, their contract pharmacy policy will exempt Arkansas covered entities and include claims data submission.
Contact:
support@340besp.com
Contact:
support@340besp.com
Liquidia
*Effective date subject to FDA’s final approval for Yutrepia
Contact:
support@340besp.com
Merck
An email notice was received from Merck, effective April 9, 2025, a change to their 340B contract pharmacy policy for covered entities in Nebraska.
Merck will provide 340B priced products to an unlimited number of contract pharmacies for Minnesota covered entities effective August 1, 2024, and Missouri covered entities effective August 28, 2024, through the provision of claims data. For Winrevair, the specialty contract pharmac(ies) must be within Merck’s limited pharmacy network.
Federal Grantees (except CH grantee entities) are not subject to limitations.
Contact:
340bdata@merck.com
Federal Grantees (except CH grantee entities) are not subject to limitations.
Contact:
340bdata@merck.com
Contact:
340bdata@merck.com
Federal Grantees (except CH grantee entities) are not subject to limitations.
Contact:
340bdata@merck.com
Contact:
340bdata@merck.com
Contact:
340Bdata@merck.com
Contact:
340Bdata@merck.com
Contact:
340Bdata@merck.com
Mallinckrodt
Effective July 17, 2024, Mallinckrodt will require a single contract pharmacy designation through FFF Enterprises, Inc. for Acthar ® claims for hospital covered entities using their limited distribution network.
Contact:
Novo Nordisk
There are no changes to wholly-owned pharmacies.
Contact:
support@340besp.com
Federal Grantees not subject to limitations
Contact:
support@340Besp.com340BInfo@novonordisk.com
Contact:
support@340BESP.com
Contact:
340BInfo@novonordisk.com
Contact:
340BInfo@novonordisk.com
Effective January 1st, 2021, Novo Nordisk will restrict 340B priced product to Contract Pharmacies for hospital Covered Entities. Federal Grantees not subject to limitations.
Contact:
340BInfo@novonordisk.com
Novartis
Effective August 1, 2024, Novartis will allow hospital covered entities located in Minnesota to place “Bill to/Ship to” replenishment orders to their HRSA designated contract pharmacies.
Contact:
Contact: Novartis.340B@novartis.com
Contact: Novartis.340B@novartis.com
Contact:
Novartis.340B@novartis.com
Contact: Novartis.340B@novartis.com
Organon
Contact:
support@340BESP.com
Contact:
support@340BESP.com
Contact:
support@340BESP.com
Pfizer
Effective August 28, 2024, Pfizer will exempt Missouri hospital covered entities from its 340B contract pharmacy policy
Contact:
340BCP@pfizer.com
Federal Grantees not subject to limitations.
Contact:
340BCP@pfizer.com
Effective July 1, 2024, Pfizer will allow Maryland 340B covered entities to access 340B ceiling price for Pfizer products affected by their contract pharmacy policy. For Vyndmax and Vyndaquel, the specialty contract pharmacies must be part of the VYNDA Network. For Pfizer’s oral oncology medications, the specialty contract pharmacy must be part of Pfizer’s DON.
Federal Grantees not subject to limitations.
Contact:
340BCP@pfizer.com
Effective July 1, 2024, Pfizer will allow Maryland 340B covered entities to access 340B ceiling price for Pfizer products affected by their contract pharmacy policy. For Vyndmax and Vyndaquel, the specialty contract pharmacies must be part of the VYNDA Network. For Pfizer’s oral oncology medications, the specialty contract pharmacy must be part of Pfizer’s DON.
Federal Grantees not subject to limitations.
Contact:
340BCP@pfizer.com
Federal Grantees not subject to limitations.
Contact:
340BCP@pfizer.com
Effective June 6th, 2024, Pfizer will allow West Virginia and Louisiana 340B covered entities to access 340B ceiling price for Pfizer products affected by their contract pharmacy policy.
Federal Grantees not subject to limitations.
Contact:
340BCP@pfizer.com
Contact:
support@340besp.com
Effective November 1st, 2023, Pfizer will include additional products to the defined distribution model currently in place for Xeljanz. They will only provide the 340B price to a single Contract Pharmacy if the hospital covered entity doesn’t have an in-house pharmacy.
Federal Grantees not subject to limitations.
*No modifications to Pfizer’s DON policy
Contact:
340BCP@pfizer.com
Federal Grantees not subject to limitations.
Contact:
340BCP@pfizer.com
*No modifications to Pfizer’s DON policy
Contact:
340BCP@pfizer.com
Contact:
340BCP@pfizer.com
Sandoz
Contact:
support@340besp.com
Contact:
support@340BESP.com
Sanofi
November 22, 2024, Update: Sanofi announced it is transitioning to a 340B Credit Model for Hospital Covered Entities (CAH, DSH, RRC, SCH) as well as Consolidated Health Centers (CH). The Credit Model effective dates are below:
January 6, 2025: CAH, DSH, RRC, SCH
March 1, 2025: CH
Beacon will be the platform to capture Claim Submission, Validation, and 340B Credit Payment Process.
Sanofi also announced changes to their Contract Pharmacy Policy effective January 6, 2025, for Hospital Covered Entities and a March 1, 2025, effective date for Consolidated Health Centers.
Contact:
Sanofi340BOperations@Sanofi.com
arrangements in Missouri. Covered Entities that currently have a contract pharmacy designation in place through 340B ESP™ will have that designation canceled and must begin submitting claims data to have access to 340B pricing at their contract pharmacies. This policy is effective August 28, 2024. Contact: Sanofi340BOperations@Sanofi.com
Effective September 23, 2024, Sanofi is requiring certain Arkansas-based 340B hospitals (CAH, DSH, RRC and SCH) to provide evidence or attestation that they “retain legal title to Sanofi 340B-priced drugs delivered to [their] contract pharmacies until the contract pharmacies dispense those drugs to 340B-eligible patients.” The 340B Integrity Initiative is for Arkansas based community pharmacies and certain Arkansas-based 340B hospitals only. Consolidated Health Center Program (CH) is exempt from the Arkansas-based policy.
Contact: Sanofi340BOperations@Sanofi.com
Contact:
Sanofi340BOperations@Sanofi.com
Contact:
Sanofi340BOperations@Sanofi.com
based contract pharmacies by submitting claims data through the 340B ESP™ platform for each of the Covered Entity’s contract pharmacy
arrangements in Missouri. Covered Entities that currently have a contract pharmacy designation in place through 340B ESP™ will have that designation canceled and must begin submitting claims data to have access to 340B pricing at their contract pharmacies.
Effective August 1, 2024, Sanofi will allow covered entities located in Maryland and Mississippi to place “Bill to/Ship to” replenishment orders to their HRSA designated contract pharmacies located within the respective states through the provision of claims data.
Contact:
Sanofi340BOperations@Sanofi.com
Contact:
Sanofi340BOperations@Sanofi.com
Contact:
Sanofi340BOperations@Sanofi.com
Effective March 1st, 2021, Sanofi will only provide 340B priced product to a Contract Pharmacy if Covered Entity provides Claims Level Detail via 340B ESP platform.
Contact:
Sumitomo
support@340besp.com
Contact:
support@340besp.com
Kansas, Maryland, Minnesota, Mississippi exception to Sumitomo contract pharmacy policies with claims data from 45 days of dispense.
Contact:
support@340besp.com
Louisiana and Arkansas covered entities are not subject to limitations.
Contact:
support@340besp.com
Sobi
Contact:
support@340besp.com
Takeda
Federal Grantees not subject to limitations
Contact:
support@340besp.com
Federal Grantees not subject to limitations
Contact:
support@340besp.com
Effective January 22nd, 2024, Takeda will only provide 340B pricing for select products to a single independent contract pharmacy or wholly owned contract pharmacy(ies) within 40 miles* of the parent site through provision of claims data via 340B ESP if a hospital covered entity doesn’t have an in-house pharmacy. If a hospital covered entity does have an in-house pharmacy, it may also designate its wholly owned contract pharmacy(ies) through provision of claims data via 340B ESP.
Federal Grantees not subject to limitations
*Exception: Entyvio
Contact:
Teva
Contact:
support@340besp.com
Contact:
support@340besp.com
Contact:
support@340besp.com
Contact:
support@340BESP.com
Contact:
support@340Besp.com
Contact:
support@340Besp.com
UCB
Contact:
340B@ucb.com
Contact:
340B@ucb.com
Contact:
340B@ucb.com
Effective October 2nd, 2023, UCB updated its contract pharmacy policy to exclude wholly owned (and common ownership) pharmacy exemption. UCB will only provide 340B pricing to a single contract pharmacy located within 40 miles of the parent site if a hospital covered entity doesn’t have an in-house pharmacy.
Federal Grantees not subject to limitations
Contact:
340B@ucb.com
Contact:
340B@ucb.com
United Therapeutics
Contact:
340B@unither.com
Vertex
Contact:
support@340besp.com
Viatris
Effective August 28, 2024, Viatris will exempt Missouri hospital covered entities from its 340B contract pharmacy policy
Contact:
support@340besp.com
Contact:
support@340besp.com
Woodward
*12 additional NDCs effective March 15th, 2023
Contact:
340b-clientsservices@
directcustomersolutions.com
340B